New axSpA Criteria: Who gets left out?
Dr. Nelly Ziade discusses abstract OP0236, OP0239, and POS0190 EULAR 2026.
Watch video →What's hot!
View all perspectives
What's Hot
What Happens when CAR-T Fails Managing Disease Recurrence
Dr. Alfred Kim discusses abstracts OP0076 and OP0333 presented at EULAR 2026.
Watch video →
‘Strong’ Treatment Predictions in Inflammatory Myositis
Dr. Janet Pope, reports on abstracts POS0264 and OP0166, presented at the 2026 EULAR meeting in London.
Watch video →
Imaging in Subclinical Psoriatic Arthritis
Dr. Antoni Chan discusses abstract OP068 presented at EULAR 2026.
Watch video →
Are we failing in the treatment of RA-ILD?
Dr. Janet Pope discusses treatment of RA-ILD after attending the "How to Treat (HOT)" session on RA-ILD at EULAR 2026.
Watch video →
PsA Potpourri: Probiotics & Head-to-Head Data
Dr. Peter Nash reports on abstracts POS0290 and LB0001 at EULAR 2026.
Watch video →
Combination Biologics in PsA: MRI Findings from AFFINITY
Dr. Artie Kavanaugh reports on abstract OP0186 presented at EULAR 2026 in London.
Watch video →
How Many CAR-Ts Do We Need to Test Drive?
Dr. Janet Pope reviews CAR-T therapy at 2026 EULAR 2026, and the issues and questions that remain with its use in rheumatology.
Watch video →
BMI Outranks Treatment in PsA Outcomes?
Dr. Peter Nash reports on abstract OP0187 presented at EULAR 2026 in London.
Watch video →
Dietary Interventions in PsA
Dr. Peter Nash reports on several abstracts at the 2026 EULAR meeting in London, including: OP069; OP070 and POS0050.
Watch video →
Low dose Blinatumomab: Many Relapse with an Unexpected Surprise
Dr. Alfred Kim discusses abstract OP0203 presented at EULAR 2026 in London.
Watch video →
RA BRIDGE and RA BRANCH trials: Baricitinib and VTE Risk
Drs. Mrinalini Dey and Jon Giles discuss abstract LB0009 presented at EULAR 2026 in London
Watch video →
Day 4 Recap: EULAR 2026
Join Drs. Jack Cush, Mrinalini Dey, Antoni Chan, and Yuz Yusof. Abstracts discussed included: LB0001 LB0002 LB0003 LB0005 LB0007 LB0009 RA Plenary POS1350.
Watch video →
EULAR 2026 Recommendations: Immunization
Dr. Jiha Lee reporting from EULAR 2026 in London.
Watch video →
Making Methotrexate More Effective
Dr. Jonathan Kay reports on abstract OP0206 and OP0207 presented at EULAR 2026 in London
Watch video →
Day 3 Recap: EULAR 2026
Join Drs. Jack Cush, Jiha Lee, Nelly Ziade, and Sheila Reyes for a lively discussion. Abstracts discussed included: OP0348 POS0290 OP0342 POS1068 POS0201 POS0288
Watch video →
5 years since Patient ID001: Progress on CAR-T Therapy in RMD
Five years on, are we closer to licensing of the first CAR-T therapy in rheumatic and musculoskeletal diseases (RMD)?
Read more →
Mrinalini Dey DrMiniDey
2 months ago
#OP0219 at #EULAR2026: Real-world ASTER data suggest DORIS remission & LLDAS are achievable with anifrolumab in routine practice, assoc w ⬇️risk of organ damage accrual. Over 12m, 43% attained DORIS remission & 74% LLDAS. Low serious adverse event rates reported. @RheumNow
Md Yuzaiful Md Yusof Yuz6Yusof
2 months ago
#EULAR2026 OP0216 With the advances in biologics/cell-based therapies in #SLE, we need to define “severe refractory.” Data-driven analysis from 13 nations suggested: SLEDAI≥6 + PGA>1 + mild-moderate or severe flare (MMSf) + GC≥10 +IS. Need validation study before use @RheumNow https://t.co/K2dMSQUIgB
Mrinalini Dey DrMiniDey
2 months ago
#OP006 - Urine proteomics in LN tracks histo activity & treatment response better than proteinuria. Paired biopsies linked active disease to IFNI, IL12, complement & neut pathways- normalised in responders but persisted in non-responders. @RheumNow #EULAR2026 #EULARBest #Plenary
Md Yuzaiful Md Yusof Yuz6Yusof
2 months ago
#EULAR2026 Please find my video interview with Prof Xavier Mariette, the presenting author of Abstract OP0126: Efficacy and Safety of Ianalumab in #Sjogren disease #SjD @RheumNow
https://t.co/NEyBOD6Qj2 https://t.co/Zn1fH6eu39
Nelly ZIADE 🍀 Nellziade
2 months ago
💉 Is Izokibep (Novel IL-17i) durable in PsA at 1yr?
Phase2b/3 RCT: ~50% ACR50 at week in 343pts
OP073 #EULAR2026 @RheumNow https://t.co/M3nrKFTA7c
Nelly ZIADE 🍀 Nellziade
2 months ago
🔬 Does synovial biopsy-guided treatment outperform standard care in PsA?
YES - 68% vs 45% DAPSA remission/LDA in 45pts
OP071 #EULAR2026 @RheumNow https://t.co/cLCR7I8QAm
Janet Pope Janetbirdope
2 months ago
#Rosnilimab works!! #PD1 agonist
In #moderate to severe #RA showed fast deep responses in Ph2 #PBO CONTROLLED #rheumatoid #athritis
Seemed NOT to have sig side effects compared to some PD1 drugs that ceased development in RA
#EULAR2026 @RheumNow
#OP0202 #EULARbest https://t.co/Jz92npXdgd
Aurelie Najm AurelieRheumo
2 months ago
SUNSTAR head-to-head after failure of 1 (80+%)–2 prior b/tsDMARDs in RA TCZ vs. ABA
Confirms what we already knew:
-Primary endpoint CDAI change wk26 not different
-Composite response (persistence + low disease activity + low steroid use) 51% vs 35% p=0.034
-Better response in https://t.co/002n3sWtKs
Antoni Chan MD (Prof) synovialjoints
2 months ago
Tofacitinib achieved ASDAS inactive disease in 26.4% of patients with early #axSpA (back pain ≤2 years) vs 7.4% placebo at 16 weeks (p=0.006). First RCT of advanced therapy in very early axSpA Abstr#0241 @RheumNow #EULAR2026
Antoni Chan MD (Prof) synovialjoints
2 months ago
Day 2 of #EULAR2026 Studies to look forward today in #axSpA: new classification criteria performance, sex differences in disease progression, early disease treatment data, primary care education to reduce delays to diagnosis @RheumNow
Nelly ZIADE 🍀 Nellziade
2 months ago
🤰What happens to RA disease activity during pregnancy?
🔴 Most remain stable
🔴 70% with high disease activity at baseline improve
🔴 20% flare again post-partum
✨ACPA+ improve more
✨ Better outcomes after 2016 (after modern treatments)
OP0242 #EULAR2025 @rheumnow https://t.co/i3X566DcN6
Dr. John Cush RheumNow
2 months ago
RheumNow’s expanded coverage of the #EULAR2026 Annual Meeting is sponsored by Bristol Myers Squibb and UCB. RheumNow and its faculty independently select all coverage content.
People with rheumatic and musculoskeletal diseases (RMD) are at risk of a number of comorbidities, from cardiovascular diseases to cognitive impairment and fractures. The 2026 EULAR Congress showcased new data and ideas around various comorbidities and drug safety issues in people with an RMD – highlighting the need for integrated care. Here are five abstracts to consider.
sheila RHEUMarampa
2 months ago
Roc-SpA study
Active axSpA dse + inad response to TNFi ➡️switch or cycled
No significant diff in ASDAS40 at wk24 bet IL-17i & 2nd TNFi
Switching to IL-17i not superior to cycling to 2nd TNFi after inad. response to 1st TNFi
Shared decision is key
AbsOP0235 @RheumNow #EULAR2026 https://t.co/3UP37IEgXv
Md Yuzaiful Md Yusof Yuz6Yusof
2 months ago
#EULAR2026 OP002 In 20 active #lupus nephritis patients with paired kidney biopsy at baseline & 1 yr, urine proteomics showed histology response correlated with restoration of immune, coagulation and ECM-remodelling pathways. Need to advance this liquid biopsy in clinic @RheumNow https://t.co/KaZSYlA9V1
